<DOC>
	<DOCNO>NCT01159691</DOCNO>
	<brief_summary>The study intend collect data gastrointestinal symptom ( swallow disorder , heartburn , feel fullness , nausea , vomit , abdominal pain , diarrhea ) patient satisfaction everyday practice condition change treatment Neupro® transdermal patch patient suffer idiopathic Parkinson´s Disease gastrointestinal symptom treat oral antiparkinson drug . The objective study ascertain whether switch therapy Neupro® transdermal patch provide relief gastrointestinal symptom .</brief_summary>
	<brief_title>Change Gastrointestinal Complaints After Switch From Oral Parkinson 's Disease Treatment Neupro® Transdermal Patch</brief_title>
	<detailed_description>Routine treatment per approve label Europe accordance term local marketing authorization Neupro® .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>The decision prescribe Neupro® must make physician independently his/her decision include patient study The patient 's treatment must accordance term local marketing authorization ( MA ) Neupro® The patient must diagnosis Idiopathic Parkinson 's disease The patient must sign Consent form regard study information , data transfer use Patient suffer gastrointestinal symptom treat oral Parkinson 's medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Switch oral therapy patch</keyword>
</DOC>